Clinical significance of circulating biomarkers of immune-checkpoint molecules with atezolizumab plus bevacizumab therapy in unresectable hepatocellular carcinoma-Reference-Cited by-同舟云学术

Clinical significance of circulating biomarkers of immune-checkpoint molecules with atezolizumab plus bevacizumab therapy in unresectable hepatocellular carcinoma

Published:2024-07-04 Issue: Volume: Page:
ISSN:1936-0533
Container-title:Hepatology International
language:en
Short-container-title:Hepatol Int

Author:

Chuma Makoto^ORCID,Uojima Haruki,Toyoda Hidenori,Hiraoka Atsushi,Arase Yoshitake,Atsukawa Masanori,Itokawa Norio,Okubo Tomomi,Tada Toshifumi,Numata Kazushi,Morimoto Manabu,Sugimori Makoto,Nozaki Akito,Iwasaki Shuichiro,Yasuda Satoshi,Koshiyama Yuichi,Mishima Yusuke,Tsuruya Kota,Tokoro Chikako,Miura Yuki,Hidaka Hisashi,Kumada Takashi,Kusano Chika,Kagawa Tatehiro,Maeda Shin

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s12072-024-10680-8.pdf

Reference30 articles.

1. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424

2. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182–236

3. Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim T-Y, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382(20):1894–1905

4. Kulkarni AV, Tevethia H, Kumar K, Premkumar M, Muttaiah MD, Hiraoka A, et al. Effectiveness and safety of atezolizumab-bevacizumab in patients with unresectable hepatocellular carcinoma: a systematic review and meta-analysis. EClinical Med. 2023. https://doi.org/10.1016/j.eclinm.2023.102179

5. Zhu AX, Abbas AR, de Galarreta MR, Guan Y, Lu S, Koeppen H, et al. Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma. Nat Med. 2022;28(8):1599–1611